NTRK1 and acute myeloid leukemia: From large-scale whole-exome or whole-genome studies, it has been described that approximately 60% of patients with AML have discrete mutations in receptor tyrosine kinases or downstream targets such as RAS/MAPK signaling that are predicted to secondarily activate mTOR signal transduction.